Hospitals are thrilled that they’re now able to offer cancer patients pioneering CAR-T treatments, but they’re also running into the omnipresent problem surrounding these and other next-generation therapies: cost.

In a speech Wednesday at the Personalized Medicine Conference, Dr. Betsy Nabel, the president of Brigham and Women’s Hospital, said her hospital and others in the Partners HealthCare system are not being reimbursed fully when they treat patients with CAR-T therapies, leaving the providers to subsidize the treatments.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • I believe that process cost universities doing the research aproximately 20,000 per patient to regrow the cells outside the body and so the rest of the 400,000 is likely for some patent holder. Therefore I think there’s going to be an industry of sending patients to China for this therapy where they not worried about US patents .

  • Thank you for keeping the public up to date on new research and treatments for cancer. My husband passed away recent look y from Sarcoma. No existing treatments could stop his disease and least of all alleviate his pain. I am still very upset at the Sarcoma center for their lack of communication into clinical trials and innovative therapies to offer patients. Keep up the good work.

  • Wonderful to trade of upcoming new research and new treatment for cancer. Keep up the good work of informing the public of what is in the near future.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy